allergy banner

Videos


Allergy Ranks Highest Impact Factor in Allergy



We are thrilled to announce that the 2024 journal Impact Factors stablished by Clarivate has been released, and we are immensely proud to share that Allergy has been recognised with a Impact Factor of 12.6 as the number one journal in our speciality of Allergy and Clinical Immunology. This outstanding achievement is a testament to the entire team's unwavering commitment and hard work.

The success of Allergy is rooted in several key factors:
Full Commitment and Hard Work: The dedication of our editorial and support teams has been instrumental in driving the journal to new heights.
Rapid Decisions for Submissions: Our efficient submission process ensures that authors receive timely and comprehensive feedback.
Extensive and High-Quality Reviews: We maintain rigorous peer review standards to ensure the publication of only the highest quality research.
Timely Publications: Speedy yet thorough processing of manuscripts guarantees that important research reaches the community promptly.
High Numbers of Impressions and Downloads: The significant engagement with our published papers highlights the journal’s influence and reach within the scientific community.

On behalf of the EAACI Executive Committee, it is our pleasure to extend our heartfelt gratitude to the entire Allergy team.

Special thanks to our Editor-in-Chief, Cezmi Akdis, for his visionary leadership, and our Deputy Editors, Ioana Agache and Marek Jutel, for their invaluable contributions. We also recognize the vital roles of our Associate Editors, including Heimo Breiteneder, Thomas Eiwegger, Wytske Fokkens, Emma Guttman-Yassky, David Jackson, Kari Nadeau, Robyn O’Hehir, Liam O’Mahony, Oliver Pfaar, Alexandra Santos, Claudia Traidl-Hoffmann, De Yun Wang, and Luo Zhang, along with the entire editorial board for their expertise and dedication.

In addition, our heartfelt thanks go to our Managing Editor, Laura Alberch; Graphics Editor, Anna Globinska; Social Media Editor, Ruya Kilic Ogulur; Associate Managing Editor, Marisa McGarry; Production Editor, Sathish Asokan Kannan, and Journal’s Publishing Manager, Lisbeth Cranfield.

Together, we have set a new standard of excellence in Allergy and Clinical Immunology, and we look forward to continuing this upward trajectory. Thank you to everyone who has contributed to making #Allergy a leader in our field!

Maria Torres
EAACI President

Free access

Articles


Early-life exposure to residential greenness and risk of asthma in a U.S. bronchiolitis cohort

Feleszko W, Makrinioti H, Nalej M, et al. Allergy. First published:21 October 2024

Redefining tryptase norms in the pediatric population reveals sex-based differences: Clinical implications

Puel, M., Rossignol, J., Devin, C., et al. Allergy. First published: 19 October 2024

The IL-4–IL-4Rα axis modulates olfactory neuroimmune signaling to induce loss of smell

Hara Y, Jha MK, Huang JY, et al. Allergy. First published:17 October 2024

Transcriptomic evidence for T cell-fibroblast-keratinocyte axis via IL-13-periostin-integrin in atopic dermatitis

Tran, N.Q.V., Kobayashi, Y., Nakamura, Y., et al. Allergy. First published:17 October 2024

Vitamin D in early life and risk of daily registered childhood infection episodes

Brustad, N., Kyvsgaard, J.N., Pedersen, C.-E.T., et al. Allergy. First published:16 October 2024

A fungal spore calendar for England: Analysis of 13 years of daily concentrations

Symon, F.A., Anees-Hill, S., Satchwell, J., et al.Allergy. First published: 16 October 2024

Farm-dust mediated protection of childhood asthma: Mass cytometry reveals novel cellular regulation

Beerweiler CC, Salvermoser M, Theodorou J, et al. Allergy. First published: 14 October 2024

Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents

Jackson DJ, Wechsler ME, Brusselle G, Buhl R.Allergy. First published: 12 October 2024

Baked milk diet is associated with improved quality of life and growth parameters in milk-allergic children

Wong, L.S.Y., Groetch, M., Bahnson, H.T., et al.Allergy. First published: 09 October 2024

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study

Soegiharto R, Alizadeh Aghdam M, Sørensen JA, et al. Allergy. First published: 08 October 2024

The epithelial barrier theory and its associated diseases

Sun N, Ogulur I, Mitamura Y, et al. Allergy. First published: 07 October 2024

Cutaneous reactions during Helicobacter pylori eradication therapy referred to an Allergy Department

Galleani, C., Peñalver, M.J., Barranco, R., et al. Allergy. First published: 05 October 2024

An algorithm for the diagnosis of betalactam allergy, 2024 update

Doña, I., Salas, M., Moreno, E.,et al. Allergy. First published: 04 October 2024

An algorithm for the diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity, 2024 update

Doña, I., Sáenz de Santa María, R., Moreno, E.M.,et al. Allergy. First published: 04 October 2024

Ushering in a new era in food allergy management with EAACI guidelines

Sicherer, S.H. Allergy. First published: 04 October 2024

Notch4 regulatory T cells and SARS-CoV-2 viremia shape COVID19 survival outcome

Benamar M, Lai PS, Huang C-Y, et al. Allergy. First published: 03 October 2024

Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils

Buchheit KM, Shaw D, Chupp G, et al. Allergy. First published: 02 October 2024

Epicutaneous immunotherapy for the treatment of peanut allergy

Ravindran M, Sampson HA, Kim EH, et al. Allergy. First published: 28 September 2024

Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy

Bachmeier-Zbären N, Celik A, van Brummelen R, et al. Allergy. First published: 28 September 2024

Regulatory T cells and their role in allergic disease

Conrad ML, Barrientos G, Cai X, et al. Allergy. First published: 27 September 2024

Development and acceptability of a decision-aid for food allergy Oral immunotherapy in children

Anagnostou A, Abrams EM, Carver M, et al. Allergy. First published: 276 September 2024

How type-2 dendritic cells induce Th2 differentiation: Instruction, repression, or fostering T cell-T cell communication?

Ronchese F, Webb GR, Ochiai S, Lamiable O, Brewerton M. Allergy. First published: 26 September 2024

Harnessing mass spectrometric methods for exquisite allergen product characterization

Jutel, M., Zemelka-Wiacek, M. and Pfaar, O. Allergy. First published: 26 September 2024

Citations: 342

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766

Citations: 147

EAACI guidelines: Anaphylaxis (2021 update)

Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377

Citations: 118

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990

Citations: 118

The role of peripheral blood eosinophil counts in COVID-19 patients

Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482

Citations: 114

Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease

Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449

Citations: 105

Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice

Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432

Citations: 90

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639

Citations: 88/h5>

The role of allergen-specific IgE, IgG and IgA in allergic disease

Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641

Citations: 82

COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676

Citations: 81

Advances and highlights in allergic rhinitis

Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389

Citations: 79

Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?

Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618

Citations: 76

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353

Citations: 74

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Citations: 73

Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches

Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826

Citations: 70

Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660

Citations: 69

Advances and highlights in biomarkers of allergic diseases

Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686

Citations: 69

Regulatory B cells, A to Z

Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.

Citations: 62

Advances and highlights in asthma in 2021

Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407

Citations: 62

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Citations: 61

The ingenious mast cell: Contemporary insights into mast cell behavior and function

Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99

The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414

Risk factors for severe and critically ill COVID-19 patients: A review

Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455

Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581

EAACI guidelines: Anaphylaxis (2021 update)

Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741

Advances and recent developments in asthma in 2020

Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update

Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541

Management of anaphylaxis due to COVID-19 vaccines in the elderly

Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review

Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016

Eczema herpeticum in atopic dermatitis

Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027

Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study

Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052

Direct assessment of individual skin barrier components by electrical impedance spectroscopy

Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106

Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132

Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis

Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154

Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy

Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193

Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine

Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196

Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma

Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202

Identification of Ulocladium chartarum as an important indoor allergen source

Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206

Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis

Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214

Legends of allergy and immunology: Sergio Bonini

Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229

Medical algorithm: Peri-operative management of mastocytosis patients

Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235

Open Access Agreements with Wiley



Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley

Free access

Junior Members Corner



Dear Juniors,
Meet two of the new EAACI JM representatives:



Dr. Bianca Olivieri has been elected as the new Junior Member (JM) Representative of the Food Allergy Interest Group. She is a specialist in Allergy and Clinical Immunology, having completed her residency at the Allergy and Clinical Immunology Department of the University of Verona, Italy. Currently, Dr. Olivieri works at the Allergy and Asthma Unit of Verona University Hospital. She is actively involved in the Food Allergy and Oral Food Challenges Outpatient Clinic. The Allergy Department, chaired by Professor Gianenrico Senna, is renowned for its scientific contributions in various allergy fields, including drug allergy, hymenoptera venom allergy, and mastocytosis under Dr. Patrizia Bonadonna's leadership; chronic rhinosinusitis and nasal polyps with Dr. Michele Schiappoli; and severe asthma and eosinophilic diseases with Dr. Marco Caminati.


Dr Fabio Ryser is the newly elected JM Representative for the ENT Section. He is a resident physician at the Department of Rheumatology and Immunology at the University Hospital of Bern, Switzerland specialising in type 2 inflammation, connective tissue diseases and autoinflammatory disorders. Under the supervision of PD Dr Steiner, his research focuses on diffuse type 2 chronic rhinosinusitis and the incorporation of machine learning into routine diagnostics. The research group works in a highly interdisciplinary way, collaborating with Prof. Dr Soyka from the Department of Oto-Rhino-Laryngology and Prof. Dr Brugger from the Department of Infectious Diseases at the University Hospital Zurich. He will bring a new multidisciplinary approach to the team and a focus on new methodologies for high precision medicine.

Best regards,
The Junior Member Assembly


EAACI Patients Organisation Committee Corner



The POC Reunion in the Annual Congress 2023



The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.

Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.

Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.

The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.

Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.

Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.

The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.